Clinical trials with antiviral drugs against COVID‐19: some progress and many shattered hopes

  title={Clinical trials with antiviral drugs against COVID‐19: some progress and many shattered hopes},
  author={Harald Br{\"u}ssow},
  journal={Environmental Microbiology},
  pages={6364 - 6376}
  • Harald Brüssow
  • Published 14 September 2021
  • Medicine
  • Environmental Microbiology
Summary Vaccines and drugs are the cornerstones in the fight against the SARS‐CoV‐2 pandemic. While vaccines were a success story, the development of antiviral drugs against SARS‐CoV‐2 turned out to be difficult. For an accelerated use of antivirals in the clinic, most SARS‐CoV‐2 antivirals represented repurposed drugs. The present article summarizes the outcomes of clinical trials with antiviral drugs in COVID‐19 patients. Many antiviral drugs failed to demonstrate beneficial effects or showed… 
Host‐modifying drugs against COVID‐19: some successes, but not yet the breakthrough
The trials showed a clear need for new drugs instead of repurposed drugs and drugs that specifically target the SARS‐CoV‐2 virus or the pathology developing in COVID‐19 patients.
Pulmonary surfactant as a versatile biomaterial to fight COVID-19
Pulmonary surfactant can be regarded as a versatile biomaterial to combat respiratory infections, in particular COVID-19, and can be repurposed to enhance drug spreading along the respiratory epithelium and to promote intracellular drug delivery.
Detection of significant antiviral drug effects on COVID-19 using viral load and PCR-positive rate in randomized controlled trials
To evaluate the effects of antiviral drugs against coronavirus disease (COVID-19), the sample size needed to detect significant differences in daily viral load in randomized controlled trials was calculated using simulated viral loads that mimicked longitudinal clinical data.


Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates
Hydroxychloroquine did not confer protection against SARS-CoV-2 infection or reduce the viral load after infection in macaques; these findings do not support the use of hydroxy chloroquine as an antiviral drug treatment of COVID-19 in humans.
No shortcuts to SARS-CoV-2 antivirals
The study by Tummino et al. (1) raises concerns that many drug candidates that showed antiviral activity in hypothesis-free cellular screens and were then repurposed to treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections may be scientific dead ends.
Drug-induced phospholipidosis confounds drug repurposing for SARS-CoV-2
Screening for drugs that don't work In the battle against COVID-19, drugs discovered in repurposing screens are of particular interest because these could be rapidly implemented as treatments.
Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results
These Remdesivir, Hydroxychloroquine, Lopinavir and Interferon regimens appeared to have little or no effect on hospitalized COVID-19, as indicated by overall mortality, initiation of ventilation and duration of hospital stay.
Efficacy and Safety of Lopinavir/Ritonavir or Arbidol in Adult Patients with Mild/Moderate COVID-19: An Exploratory Randomized Controlled Trial
LPV/r or arbidol monotherapy present little benefit for improving the clinical outcome of patients hospitalized with mild/moderate COVID-19 over supportive care, and no apparent adverse event occurred in the control group.
Interferon responses in viral pneumonias
Are interferon-mediated antiviral immune responses beneficial or detrimental in COVID-19? The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak quickly developed into a pandemic
Remdesivir for the Treatment of Covid-19 — Final Report
The data show that remdesivir was superior to placebo in shortening the time to recovery in adults who were hospitalized with Covid-19 and had evidence of lower respiratory tract infection.
Clofazimine broadly inhibits coronaviruses including SARS-CoV-2.
It is shown that clofazimine, an anti-leprosy drug with a favourable safety profile, possesses pan-coronaviral inhibitory activity, and can antagonize SARS-CoV-2 and MERS- CoV replication in multiple in vitro systems, and is an attractive clinical candidate for outpatient treatment and remdesivir-based combinatorial therapy for hospitalized COVID-19 patients.
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
In this study of adult patients admitted to hospital for severe COVID-19, remdesivir was not associated with statistically significant clinical benefits, however, the numerical reduction in time to clinical improvement in those treated earlier requires confirmation in larger studies.
U.K. megatrial outshines other drug studies.
In a sea of small, single institution studies, Recovery, with 12,000 patients and hundreds of participating hospitals, stands out—and offers lessons for the few other megatrials that have been slow off the mark.